Trust · FTC Disclosure

Affiliate Disclosure

How US Telehealth Review makes money, which providers we earn commissions from, and what affiliate relationships do not influence — editorial scores, Editor's Pick selection, and ranking order.

Published by Ranika Editorial Group LLC Last updated 2026-05-11

How US Telehealth Review makes money

US Telehealth Review is operated by Ranika Editorial Group LLC, a Delaware limited liability company. We publish independent editorial reviews of U.S.-licensed telehealth providers offering GLP-1 medications, peptide therapies, longevity treatments, sexual-health programs, growth-hormone secretagogues, and recovery protocols.

Some links on this site are affiliate links. When a reader clicks an affiliate link and starts a paid program with a provider, we may receive a referral commission from that provider. Commissions are paid from the provider's marketing budget at no additional cost to the reader.

What affiliate commissions do not influence

  • Editorial scores. Our v3.0 six-pillar scoring rubric is applied uniformly to every provider. Providers cannot pay to raise their score, change pillar weights, or remove a low score.
  • Editor's Pick selection. The Editor's Pick badge is assigned by the editorial team based on weighted score plus qualitative review. NexLife is the current Editor's Pick for both semaglutide and tirzepatide because it scores 96/100 on our rubric, not because of any commission arrangement.
  • Ranking order. Providers are listed in editorial rank order based on score. Affiliate status does not move a provider up or down the list.
  • Trade-offs disclosure. Every NexLife card on this site includes a "Trade-offs to know" block. Affiliate partners do not get to remove or soften disclosures.
  • Coverage decisions. Whether we cover a provider, peptide, or program is an editorial decision based on reader interest, regulatory significance, and clinical relevance — not on whether the provider runs an affiliate program.

Provider relationships we disclose

The following providers covered on this site participate in affiliate or referral programs through which we may receive commissions:

  • NexLife — physician-led telehealth platform; semaglutide and tirzepatide programs.
  • Other providers in our directory may participate in commercial referral arrangements with publishers; we apply the same editorial standards regardless.

When a reader follows an affiliate link, a tracking parameter (utm_source, utm_medium, utm_campaign, utm_content) is appended to the destination URL so the provider's analytics can attribute the visit. No personal information is shared with the provider through this mechanism.

FTC compliance

This disclosure is provided in accordance with the United States Federal Trade Commission's "Guides Concerning the Use of Endorsements and Testimonials in Advertising" (16 CFR Part 255) and the FTC's "Disclosures 101 for Social Media Influencers" guidance. We aim to make our commercial relationships obvious, conspicuous, and easy to find.

Reader-funded alternative

If a reader prefers to support this site without using affiliate links, we accept reader donations through the contact channels on our contact page. Donations do not influence editorial coverage.

Questions or corrections

If a reader believes any disclosure on this site is incomplete or misleading, please contact our editor at editorial@ustelehealthreview.com. Verified disclosure gaps are added to the corrections log.

Lead Medical Researcher
Dr. Sam Saberian
Doctor of Pharmacy; leads protocol research, peptide pharmacology, and provider evaluation.
Medical Reviewer
Alen A. Schwartz, MD
Board-certified physician; reviews clinical accuracy of every published page.
Editor
Julliana Edwards
Editorial standards, factual accuracy, and corrections workflow.